Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements.
Takeda Pharmaceutical will adopt value-based pricing for expensive biopharmaceuticals starting in Europe, becoming the first Japanese drugmaker to test a method that charges only patients whose conditions have improved and possibly igniting a debate for introduction here.
Takeda is looking to adopt the pricing mechanism for a stem cell therapy called Alofisel for a complication of Crohn's disease. Because of the complex production method that involves cell cultivation, the drug is expected to carry a price tag of an estimated 60,000 euros ($67,000).
